MLICM
EWTX icon

Metropolitan Life Insurance Company (MetLife)’s Edgewise Therapeutics EWTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,081
Closed -$56.2K – 720
2024
Q1 		$56.2K Buy
3,081
+464
+18% +$7.38K ﹤0.01% 1346
2023
Q4 		$28.6K Hold
2,617
– – ﹤0.01% 1750
2023
Q3 		$15K Buy
2,617
+525
+25% +$3.57K ﹤0.01% 2028
2023
Q2 		$16.2K Hold
2,092
– – ﹤0.01% 2042
2023
Q1 		$14K Sell
2,092
-712
-25% -$6.6K ﹤0.01% 2041
2022
Q4 		$25.1K Hold
2,804
– – ﹤0.01% 1886
2022
Q3 		$27.6K Hold
2,804
– – ﹤0.01% 1839
2022
Q2 		$22.3K Hold
2,804
– – ﹤0.01% 1996
2022
Q1 		$27.2K Sell
2,804
-8,328
-75% -$107K ﹤0.01% 1942
2021
Q4 		$170K Buy
+11,132
New +$200K ﹤0.01% 2134

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s EWTX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Edgewise Therapeutics (EWTX) in Q2 2024, closing a stake of 3,081 shares — an estimated $56.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in EWTX in Q4 2021 and held it in 10 quarters. The position peaked at $170K in Q4 2021. 140 funds tracked by Wall St. Rank hold EWTX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Edgewise Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,081 Edgewise Therapeutics shares in Q2 2024, an estimated $56.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Edgewise Therapeutics in Q4 2021 and held it in 10 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Edgewise Therapeutics position peaked at $170K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.